Literature DB >> 9155636

Intranasal antigen targeting to MHC class II molecules primes local IgA and serum IgG antibody responses in mice.

D P Snider1, B J Underdown, M R McDermott.   

Abstract

Covalent conjugates of hen egg lysozyme (HEL) and anti-major histocompatibility complex (MHC) class II monoclonal antibodies (mAb) were used to immunize mice intranasally. Three weeks after intranasal (IN) priming, mice responded rapidly to IN challenge with a mixture of HEL and cholera toxin (CT), by producing large titres of anti-HEL IgA and IgG1 antibody in serum, and IgA antibody in nasal secretions. No secondary response to HEL plus CT occurred in mice that received no priming or mice primed with HEL alone. The secondary serum IgG antibody response was dominated by the IgG1 subclass. HEL combined with CT adjuvant worked much better than HEL alone in producing the secondary response. Control conjugates, containing an IgG isotype-matched mAb without specificity for mouse tissues, provided poor priming. Mice expressing MHC class II molecules, to which the anti-MHC II mAb could not bind, produced a weak antibody response compared with those that expressed the appropriate. MHC class II molecule. Our results demonstrate that immunotargeting to MHC class II molecules via the IN route allows priming of the local IgA and circulating IgG antibody, and indicate that this technique is a feasible approach for delivery of subunit vaccines in the upper respiratory tract.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9155636      PMCID: PMC1456616          DOI: 10.1111/j.1365-2567.1997.00323.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  Combined oral/nasal immunization protects mice from Sendai virus infection.

Authors:  J G Nedrud; X P Liang; N Hague; M E Lamm
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

2.  Improved silver staining procedure for fast staining in PhastSystem Development Unit. I. Staining of sodium dodecyl sulfate gels.

Authors:  J Heukeshoven; R Dernick
Journal:  Electrophoresis       Date:  1988-01       Impact factor: 3.535

3.  Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC.

Authors:  G Carayanniotis; B H Barber
Journal:  Nature       Date:  1987 May 7-13       Impact factor: 49.962

4.  Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin.

Authors:  C O Elson; W Ealding
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

5.  Defense mechanisms against primary influenza virus infection in mice. I. The roles of interferon and neutralizing antibodies and thymus dependence of interferon and antibody production.

Authors:  T Iwasaki; T Nozima
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

Review 6.  The structural basis for immunity in the respiratory tract.

Authors:  M R McDermott; A D Befus; J Bienenstock
Journal:  Int Rev Exp Pathol       Date:  1982

7.  Nasal lymphoid tissue in the rat.

Authors:  B J Spit; E G Hendriksen; J P Bruijntjes; C F Kuper
Journal:  Cell Tissue Res       Date:  1989-01       Impact factor: 5.249

8.  Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles.

Authors:  E S Cahill; D T O'Hagan; L Illum; A Barnard; K H Mills; K Redhead
Journal:  Vaccine       Date:  1995-04       Impact factor: 3.641

9.  Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes.

Authors:  A de Haan; H J Geerligs; J P Huchshorn; G J van Scharrenburg; A M Palache; J Wilschut
Journal:  Vaccine       Date:  1995-02       Impact factor: 3.641

10.  Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins.

Authors:  R Weltzin; P Lucia-Jandris; P Michetti; B N Fields; J P Kraehenbuhl; M R Neutra
Journal:  J Cell Biol       Date:  1989-05       Impact factor: 10.539

View more
  5 in total

1.  Anti-class II monoclonal antibody-targeted Vibrio cholerae TcpA pilin: modulation of serologic response, epitope specificity, and isotype.

Authors:  J Y Wu; R K Taylor; W F Wade
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

2.  Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.

Authors:  N K Childers; K L Miller; G Tong; J C Llarena; T Greenway; J T Ulrich; S M Michalek
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its vlosely related homologue, the B subunit of cholera toxin.

Authors:  D G Millar; T R Hirst; D P Snider
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Loss of sialic acid binding domain redirects protein σ1 to enhance M cell-directed vaccination.

Authors:  Dagmara Zlotkowska; Massimo Maddaloni; Carol Riccardi; Nancy Walters; Kathryn Holderness; Gayle Callis; Agnieszka Rynda-Apple; David W Pascual
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

5.  Increased generation of HIV-1 gp120-reactive CD8+ T cells by a DNA vaccine construct encoding the chemokine CCL3.

Authors:  Inger Øynebråten; Jorma Hinkula; Agnete B Fredriksen; Bjarne Bogen
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.